Hims & Hers (NYSE: HIMS ) is no longer just a DTC telehealth storefront. It is fast becoming a targeted health platform with loyal members and rising ARPU. It is also building the foundation to expand intoI am a retired quant with a PhD in mechanical engineering. I started off my professional career as an engineer and eventually transitioned into a hybrid developer/quantative analyst role at the investment arm of one of the nation's largest insurance companies.I ended my career as a fixed income specialist, ...

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and failing to account for rising customer acquisition costs, leading to a significant drop in share value [1][3]. Company Overview - LifeMD, Inc. is a direct-to-consumer telehealth company based in New York, providing virtual healthcare services and pharmacy offerings in areas such as men's health, obesity treatment, and chronic care [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025, with a deadline of October 27, 2025, for investors to seek lead plaintiff status [1][2]. - The complaint claims that LifeMD raised its 2025 guidance recklessly, which contributed to the misrepresentation of its financial health [3]. Financial Impact - Following the revelation of the company's financial issues, LifeMD shares experienced a dramatic decline, losing 44% of their value in a single trading session [3].

Teladoc's stock has taken a nosedive, but is there hope for recovery? Our experts break down the company's performance and future potential in this insightful analysis. Explore the exciting world of Teladoc (TDOC -0.07%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of Jul. 30, 2025. The video was published on Aug. 25, 2025. Anand C ...

“We had a great first 6 months, with 33% year-over-year growth. We have also exceeded our internal metrics across all verticals in the first seven months of the year, reinforcing the strength of our strategy. A key focus has been our investment in making the VSDHOne platform fully modular, allowing customers to adopt it module by module to fit their needs. At the same time, we’ve been prioritizing acquisitions and strategic investments that strengthen our margins, accelerate growth, and expand our ecosystem ...

Core Viewpoint - The most shorted stocks on Wall Street, including Rocket Companies Inc, Oscar Health Inc, and Hims & Hers Health Inc, are positioned precariously, with significant short interest indicating potential for volatility and short squeezes [1][2][6]. Group 1: Company Performance - Rocket Companies has seen a remarkable increase of over 75% year-to-date, with a market capitalization nearing $40 billion and 37% of its shares sold short [3]. - Oscar Health has rebounded with a 25% increase this year, maintaining a short interest just under 30% and only 1.5 days to cover, indicating a potential for a quick squeeze [4]. - Hims & Hers has experienced a staggering 170% rise over the past year, although it has recently pulled back nearly 25%. It has a market cap of $9.7 billion and 35% of its float remains shorted, making it a high-risk short position [5]. Group 2: Market Dynamics - The current market environment is characterized by high short interest ratios and thin days to cover, suggesting that Rocket, Oscar, and Hims could transition from being heavily shorted to experiencing significant upward momentum if retail traders engage [2][6]. - The presence of retail traders looking for the next potential squeeze adds to the volatility of these stocks, making them susceptible to rapid price changes [2][6].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged securities fraud related to misleading statements about its collaboration with Novo Nordisk and the promotion of illegitimate products [1][2][3] Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy® [2] Allegations of the Lawsuit - The lawsuit claims that Hims & Hers engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - It is alleged that the company failed to disclose the risks associated with its collaboration with Novo Nordisk, leading to a significant risk of termination of the partnership [2] - Novo Nordisk officially terminated its partnership with Hims & Hers on June 23, 2025, citing the deceptive practices as the reason, resulting in a stock price drop of over 34% [3] Legal Process - Investors who purchased Hims & Hers securities during the specified class period can seek to be appointed as lead plaintiff in the class action lawsuit [4] - The lead plaintiff will represent the interests of all class members and can choose a law firm to litigate the case [4] Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [5] - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [5]

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether LifeMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 5, 2025, L ...

NEW YORK, Aug. 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=162488&from=4CLASS PERIOD: April 29, ...

CASE ALLEGATIONS: Hims & Hers is a telehealth company that provides prescription medications, over- the-counter medications, and personal care products. According to the complaint, on April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk A/S, starting with the immediate sale of "a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform." The Hims & Hers class action lawsuit alleges that defendants throughout the Class Period made false and/or misleadin ...

SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, all dates inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers as well as c ...